Gilead Sciences Statement on US Food and Drug Administration Advisory Committee's ...

“Descovy represents a potential new therapeutic option for people at risk of sexually acquired HIV-1 infection. If approved for a PrEP indication, ...


View article...

Top stories of the last 30 days